Galenica

Company Profile

Galenica is one of the largest Greek pharmaceutical companies which promotes research and serves health with consistency and scientific responsibility, by developing high-quality and innovative pharmaceutical products.

Founded in 1974 by the pharmacists Denis Varelas and Basile Tamvacas, it became very soon one of the most dynamic companies in the sector with impressive rates of growth and development.

It is the first Greek company that focused on the acquisition of know-how and marketing of ethical products, through the cooperation with well established foreign research based pharmaceutical companies.

It is also focused on the development of its own proprietary hybrid pharmaceutical products, which are already exported successfully in EU and the Balkan countries (Romania, Albania, Bulgaria, Serbia), Middle East, W. Africa either through Galenica’s own organization (Romania) or through distribution agreements with local companies.

Galenica offers wide range of Rx portfolio covering the majority of therapeutic categories (Gastrenterology, Cardiology, Dermatology,  Neurology/Psychiatry, Allergiology, Gynecology, Cancer, Sensory Organs Diseases) as well as O.T.C., Consumer HealthCare high-end products in the field of self-medication and primary health care (Cough & Cold, Injuries-Pain, Muscle Pain, Diarrhea etc).

Target Partners & Collaborations

Pharmaceutical research based companies either for licensing-in or licensing-out agreements.

Technologies / Services offered or sought

• Production for third parties in our production unit of Kryoneri.
• Finished dosage forms for out-licensing in the O.T.C sector and Rx in gastroenterology, cardiology and dermatology.

• Collaboration in the preclinical phase of our R&D outcomes.
• New ethical products for in-licensing for our markets in cardiology, oncology, gastroenterology, neurology and psychiatry.

Technology and R&D

Continuously following, observing and attending the scientific and technological advances as well as the evolution of the world pharmaceutical market, Galenica operates as an open innovation model and participates in several partnerships with research institutions in Europe, USA, Japan and India.

Galenica is very active in the research and development of its own products, the development, co-development and research of new medications and treatments for different therapeutic categories, giving priority to the safety and efficacy of its high-quality pharmaceutical products.

At the level of basic research, Galenica cooperates with universities and research organizations and companies both in Greece and abroad, whereas at the level of the development and evaluation of specialized pharmaceutical applications, it participates in the implementation of clinical studies both in Greece and abroad.

Galenica has its own manufacturing facilities units for pharmaceutical products, located in Glyfa-Chalkida and Kryoneri-Attica. In these facilities, several types of pharmaceutical products are being manufactured according to the international standards and regulations, following production processes that are fully compliant with the Good Manufacturing Practice (G.M.P.) and furthermore ensure the application of all appropriate environmental protection measures.

The long tradition in the development and manufacturing of pharmaceutical products, in combination with the orientation towards a Total Quality Management, ensure the manufacturing of high-quality formulations in the following forms:

• Oral dry preparations (tablets, capsules, film-coated tablets, sachets, effervescent tablets)

• Oral, liquid solutions (syrups, suspensions, oral vials, nasal sprays)

• Solutions for injection (aseptic and fully sterilized ampoules)

• Ointments and creams

Its R&D Center is GMP approved Galenical and Analytical laboratory, in a 350m² state-of-the-art setting, designed and constructed as a GMP production unit micrograph (controlled pressure, temperature and humidity, staff flow, materials flow etc).

The R&D is focusing on:

1. Development of new hybrid products (new innovative formulations and/or new ways of administration

2. Research and development on new innovative medicines and food supplements of natural origin taking advantage of the large biodiversity of Greece’s nature as well as the vast amount of traditional medicine knowledge in collaboration with Greek universities

3. Basic research in new innovative molecules addressed to oncology with the aim to develop them up to the NDA stage.

Clients & Collaborations (NATIONAL)

In the context of its research activity GALENICA has established long-term co-operations with universities and other research bodies, aiming to create better conditions for research and development of new pharmaceutical forms and improvement of existing ones. GALENICA has managed to acquire expertise and to establish a successful partnership model through its co-operation with the Universities of Athens, Crete, Ioannina, Patras, Greek Pasteur Institute.

Clients & Collaborations (INTERNATIONAL)

One of the primary success factors of Galenica lies with its distinguished business partners all over the world. The history of many and successful partnerships gives the company the strategic advantage to select with very strict criteria the pharmaceutical products that it develops into therapeutic and business values. Indicatively here after are listed some of the companies and research organizations that Galenica collaborates with:

ALMIRALL (Spain), ADARE (USA), ALEXZA (USA), BOEHRINGER INGELHEIM (Germany),  BIOPROJET (France), DOMPE' (Italy), DR. FALK PHARMA (Germany), GEBRO PHARMA (Austria), HELSINN (Switzerland), FERRER PHARMA (Spain), JANSSEN - CILAG (USA), LABORATORIOS LESVI (Spain), MERCK KgaA (Germany), NAVEH PHARMA (Israel), NOVINTETHICAL (Switzerland), OMEGA (Belgium), PRONOVA (Norway), RECORDATI (Italy), SANOFI Group (France), THE MEDICINES COMPANY (USA), UNITED THERAPEUTICS (USA), URIACH (Spain).